Soligenix Q2 10-Q Flags Going Concern, Nasdaq Delisting Risk, and Heavy ATM Dilution
SNGX sits 39% above its 52-week low of $0.28.
Summary
Soligenix's Q2 2026 10-Q reveals a going concern warning, Nasdaq delisting risk, and massive ATM-driven dilution — shares outstanding more than doubled in six months.
Key Events · Financing and Capital Events · SNGX
-
Going Concern Warning
Management expresses substantial doubt about the company's ability to continue as a going concern, citing the need for additional capital, strategic transactions, or government funding — none of which are committed.
-
Nasdaq Delisting Risk
The company received a delisting notice on June 10, 2026, for failing to maintain a $1.00 minimum bid price. It has until December 7, 2026, to regain compliance, likely requiring a reverse stock split.
-
Massive ATM-Driven Dilution
In H1 2026, the company sold 11.5M shares via its ATM for $6.0M in net proceeds, increasing shares outstanding from 10.1M to 21.6M — a 114% increase. An additional 128,000 shares were sold in July at $0.40/share.
-
Cash Runway and Remaining ATM Capacity
Cash and equivalents stand at $9.8M as of June 30, 2026, providing runway into Q2 2028. However, only $2.4M remains on the ATM facility, and the company warns it may need to delay, reduce, or eliminate development efforts if additional capital is not secured.
Analysis · SNGX · Life Sciences
Incorporated into this prospectus supplement, Soligenix's Q2 2026 10-Q warns of a going concern, Nasdaq delisting risk, and massive ATM-driven dilution. During the first half of 2026, the company sold $6.2M in shares through its ATM, ballooning shares outstanding from 10.1M to 21.6M — a 114% increase. With only $2.4M remaining on the ATM and a cash runway into Q2 2028, management cautions that survival may hinge on securing additional capital. The stock trades at $0.39, far below the $1.00 Nasdaq minimum, and a reverse split proposal is pending. This filing confirms the company is fighting for its listing and its life.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.6% of the 330 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNGX was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.5M. The 52-week trading range was $0.28 to $6.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.